1. Home
  2. Advocacy
  3. Latest News and Practice Data
  4. Genomic testing expands under Medicare

Genomic testing expands under Medicare

The CAP's molecular oncology experts are supporting updates to a Medicare local coverage policy for Genomic Sequence Analysis Panels in the Treatment of Hematolymphoid Diseases

Why it matters: This expands coverage and improves patient access to molecular testing for acute myelogenous leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPN).

  • The policy aligns with the National Comprehensive Cancer Network guidelines and the World Health Organization classifications.

What's New: Coverage now includes newly-diagnosed or relapsed AML patients, MDS patients with nondiagnostic assessments, and MPN patients requiring risk stratification or disease monitoring.

Go Deeper: Read more about the CAP's Medicare Coverage Advocacy.

Most Recent Content

  1. Immunohistochemical Surrogates of Molecular Genetic Alterations in Soft Tissue Tumors
  2. June 24, 2025
  3. CAP talks with CMS about burdens in Medicare
  4. HHS, CMS, and insurers agree on prior authorization changes
  5. Physicians urge reinstatement of vaccine panel
  6. View All